Evidence map›Paper›PMID 42463966›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2026

[

Giulia Santo, Chiara Pozzessere, Olivier Michielin, Giuseppe Lucio Cascini, John O Prior, Francesco Cicone

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giulia SantoNuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Campus "Salvatore Venuta", Viale Europa, Catanzaro, 88100, Italy. giulia.santo@unicz.it.ORCID http://orcid.org/0000-0001-6565-0686
Chiara PozzessereDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Olivier MichielinPrecision Oncology, University Hospital of Geneva (HUG), Geneva, Switzerland.
Giuseppe Lucio CasciniDepartment of Medicine and Heath Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.
Francesco CiconeNuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Campus "Salvatore Venuta", Viale Europa, Catanzaro, 88100, Italy. cicone@unicz.it.ORCID http://orcid.org/0000-0003-4664-1965

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No specific statements regarding the use of 2-[

Indexed as

Evidence-Based MedicineFluorodeoxyglucose F18ImmunotherapyMedical OncologyNeoplasmsPositron-Emission TomographyPositron Emission Tomography Computed TomographyPractice Guidelines as TopicHumansFluorodeoxyglucose F18Immune Check Point InhibitorsMelanomaNon-Small Cell Lung CancerPositron Emission Tomography Computed TomographyTreatment monitoring

Identifiers

PMID42463966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.